Mucoadhesive tablets for buccal administration of nicotine were prepared as an alternative to the available nicotine dosage forms. Three types of tablets were developed each containing two mucoadhesive components (HPMC, K4M and sodium alginate), (HPMC, K4M and carbopol) (Chitosan and sodium alginate). For each of these types, batches were produced changing the quantity of polymers resulting in nine different formulations. The tablets were evaluated for release pattern, and mucoadhesive performance. Pharmacokinetic studies were conducted in smokers. A peak plasma concentration of 16.78±2.27 ng was obtained in two hours, which suggests potential clinical utility in nicotine replacement therapy.
Tobacco smoking related diseases constitute a major
The aim of this work was to develop mucoadhesive health problem all over the world. Chronic tobacco tablets of nicotine for buccal administration and to smoking affects all the systems of the body. Nicotine carryout its release, in vivo and pharmacokinetic study. replacement therapy has therefore been developed as an aid to smoking cessation. Though a variety of nicotine Nicotine was obtained from Merck, Germany, HPMC, replacement products are commercially available in the K4M from BDH laboratories, Sodium alginate from S.D. market, number of practical problems are associated with Fine Chemicals, Chitosan from Central Institute of each nicotine replacement therapy product available 1 .
Fisheries Tech., Cochin, India and Carbopol 934P was Drug absorption via the mucosal epithelium of the oral purchased from B. F. Goodrich and Co. Germany. cavity is an established route of systemic drug delivery, Biaxially-oriented polypropylene (BOPP) film was which is especially useful if absorption after oral supplied by Pidilite, India. The rest of the ingredients and administration is incomplete or ineffective. Furthermore, reagents were of analytical grade. oral transmucosal drug delivery provides removal of dosage form in case of need. Buccal administration of Tablets were prepared by the direct compression of the drug is highly acceptable by patients and the buccal drug with mucoadhesive polymers. Nicotine was adsorbed mucosa is relatively permeable with rich blood supply 2 .
on aerosil (colloidal silicon dioxide). To this, the rest of the excipients were added in geometric progression and Table 1 .
BOPP film was used as backing membrane. The adhesive used in making the film was water based acrylic emulsion which is a pressure sensitive adhesive. This film was cut into the required circular shape and attached manually to the tablet. The tablets were evaluated for Thickness, Hardness and weight uniformity.
In vitro bioadhesion studies were carried out using a mucoadhesive capacity versus the polymer percentage as shown by adhesion force ( fig. 1 ). From the results it can be seen that polymer having high molecular weight and high viscosity exhibited higher adhesion and increasing contact time had little effect on this. Results of in vitro release of nicotine from buccal adhesive tablets notably differed depending on quality and quantity of mucoadhesive components ( fig. 2 ).
The release rate of nicotine from mucoadhesive tablets decreased with increasing concentration of HPMC. 
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Formulation A containing only HPMC exhibited less drug release compared to formulation B and C. The tablets of modified physical balance 3 . The dissolution behavior of buccal tablets was determined using the USP XXIII method (apparatus II-paddle) 4 . Preliminary in vivo evaluation of placebo tablets were conducted on five healthy volunteers after obtaining approval from the hospital ethical committee (approval No. KH/26-12/2002), KMC, Manipal. The objectives of the study were to determine the time of adhesion, to investigate the acceptibility of different polymers and to determine any irritation or side-effects produced by the formulations. Pharmacokinetic study of nicotine buccal tablets was conducted in six healthy south Indian adult male smokers. The study was unblinded and conducted in age group between 25-40 y. Blood samples were withdrawn from the cubital forearm vein before drug administration and then 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 h after administration of the buccal tablet. Blood samples were collected in heparinised tubes, centrifuged and plasma was separated by centrifugation and frozen till further analysis. The nicotine concentration in plasma was quantitatively determined by HPLC 5 . Calculation of pharmacokinetic parameters was done using PK Solution 2.0 software supplied by Summit Research Services Montrose, USA, which is based on noncompartmental pharmacokinetic analysis. tablets showed thickness in the range of 1.20 to 1.50 mm.
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Hardness and friability were satisfactory. In vitro bioadhesion studies showed a linear dependence of the Physical parameters were found to be fairly good. The 
Plasma Concentration of nicotine (ng/ml)
Starch DC q.s to 100 100 100 100 100 100 100 100 100 www.ijpsonline.com formulation A released the drug at a controlled rate, controlled by the swelling of the polymer, followed by drug diffusion through swollen polymer and then further followed by slow erosion of the polymer. The ratio of the bioadhesive polymers HPMC and sodium alginate also altered the release rate. Sodium alginate is more hydrophilic than HPMC. It can swell rapidly, therefore decrease of sodium alginate content delays drug release. On contact of the tablets with water, sodium alginate rapidly hydrates and swells to form a gel layer over the tablet surface. Decreasing concentration of sodium absorption of nicotine from buccal formulation. The buccal mucosa may be a more favorable site for absorption of nicotine. Non keratinized and strongly supplied with blood, with a dense capillary network, it constitutes a relatively large drug absorption area. Drug can thus reach the systemic circulation directly through capillary vessels, bypassing the first pass metabolism in the intestines and liver or avoiding inactivation in the stomach 7 . This in turn contributes to higher bioavailability after administration of a smaller dose of drug. Area under the concentration-time curve AUC was found to be alginate from B to C decreased the release of nicotine. 82.4±24.0 ng/ml for 5 mg of buccal tablet. The high C Tablets with low alginate content hydrate less readily value of buccal tablets indicates rapid absorption into resulting in a slower release rate.
systemic circulation (t max =2 h), which can be readily used in smoking cessation for break through cravings. Formulation E with 30%HPMC showed a retarded release, which may be due to the gelling and slow
Since the buccal tablet remains stationary at the buccal dissolution of the polymer 6 . Formulation G released the mucosa, it is in constant contact with the buccal mucosa. drug at a faster rate due to higher carbopol. As the Hence it is able to provide good bioavailability. The carbopol content increased, there was an increase in the mucoadhesive buccal tablets showed compliance in human amount of drug released.
volunteers. The impermeable backing layer facilitates unidirectional release of nicotine, which was supported by In case of chitosan-sodium alginate, when tablets came the absence of bitter taste. Since the bioadhesive tablets into contact with buffer, chitosan rapidly absorbed a large eventually eroded, the removal of the device was not quantity of water swelled and then eroded gradually. The needed and bioadhesive tablets can be inserted chitosan/alginate tablets of formulation I, having a higher repeatedly if desired. The results of the pharmacokinetic alginate content displayed a faster release pattern study indicate that the developed buccal dosage form is compared to formulation H. In case of formulation H with able to continuously deliver nicotine within the mouth to lower alginate content, chitosan swelled due to water the buccal membranes. Hence the developed uptake. This swelling and lack of erosion gave a mucoadhesive tablet for buccal administration has a retarding effect on nicotine drug release. In vivo potential clinical usefulness as nicotine replacement evaluation of mucoadhesive tablets confirmed that the therapy for smoking cessation. mucoadhesive tablets did not cause any irritation or hindrance to the volunteers and their taste was
